|

A Study to Evaluate the Effect of AZD6793 on the Pharmacokinetics and Pharmacodynamics of Metformin in Participants With Type 2 Diabetes Mellitus

RECRUITINGPhase 1Sponsored by AstraZeneca
Actively Recruiting
PhasePhase 1
SponsorAstraZeneca
Started2026-01-14
Est. completion2026-06-18
Eligibility
Age18 Years – 70 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07433062

Summary

The purpose of this study is to examine the effect of AZD6793 on the Pharmacokinetics and Pharmacodynamics of Metformin in Participants with Type 2 Diabetes Mellitus.

Eligibility

Age: 18 Years – 70 YearsHealthy volunteers accepted
Inclusion Criteria:

* Physician-diagnosis of T2DM
* On a stable dose of metformin 2000 mg per day for at least 3 months prior to screening.
* stable glycaemic control indicated by no change in treatment for diabetes within 3 months prior to screening
* HbA1c (Hemoglobin A1c) ≤ 8.5% at screening
* Body Mass Index (BMI) within the range 18.5 to 35 kg/m2 , inclusive, at screening.

Exclusion Criteria:

* Physician diagnosis of type 1 diabetes.
* History of any clinically important disease or disorder.
* History or presence of chronic Gastrointestinal, hepatic, renal, or pancreatic disease
* History of Human immunodeficiency viruses (HIV) infection or a positive HIV test.
* History of prior episode(s) of lactic acidosis.

Conditions2

DiabetesType 2 Diabetes Mellitus

Browse More Trials

Diabetes trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.